Linoleic acid and multiple sclerosis

Publisher Website
Google Scholar
Abstract
Data from 3 double-blind trials of linoleic acid [as dietary supplement] in the treatment of multiple sclerosis (MS) were reanalyzed to examine whether inconsistency in the results was due to a relationship between patient characteristics and treatment response. The combined data consisted of neurologic assessments over 2 1/2-yr trials for 87 treated patients and 85 control patients. Treated patients with minimal or no disability at entry had a smaller increase in disability than did controls (P < 0.05). Treatment reduced the severity and duration of relapses at all levels of disability and duration of illness at entry to the trials.

This publication has 1 reference indexed in Scilit: